1. Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023.
- Author
-
Chaix ML, Terracol L, Nere ML, Stefic K, Lascoux-Combe C, Manda V, Sellier P, Maylin S, Molina JM, Liegeon G, Delaugerre C, and Salmona M
- Subjects
- Humans, France epidemiology, Male, Female, Adult, Middle Aged, Organophosphates pharmacology, Genotype, HIV Antibodies immunology, Piperazines, HIV Infections virology, HIV Infections drug therapy, HIV Infections epidemiology, HIV Infections immunology, HIV-1 drug effects, HIV-1 immunology, HIV-1 genetics, Antibodies, Neutralizing immunology, Anti-HIV Agents therapeutic use, Anti-HIV Agents pharmacology, Drug Resistance, Viral genetics
- Abstract
Surveillance studies of Transmitted Drug Resistance (TDR) are crucial in tracking the evolution of HIV epidemiology. Our aim was to investigate TDR to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs), as well as to new drugs: lenacapavir, fostemsavir. Predictive sensitivity was evaluated for maraviroc and broadly neutralizing antibodies (bNAbs) (zinlirvimab and teropavimab). Between 2020 and 2023, 85 people with HIV (PWH) were diagnosed with primary HIV-1 infection (PHI). Pol and env sequences were analyzed and TDR was characterized according to the French ANRS algorithm. The genotypic-based prediction of bNAbs sensitivity was based on HIV env amino acid signatures I108, I201, F353 for teropavimab and N325, N332, H330 for zinlirvimab. TDR to NRTIs, NNRTIs, PIs and INIs was evidenced in 8.2%, 12.9%, 4.7%, and 5.9% strains, respectively. Ten viruses were CXCR4/dual mix. All viruses were susceptible to lenacapavir (100%) and 52% harbored resistance to fostemsavir. The genotypic profile was associated with a predictive positive value (PPV) > 83% of susceptibility to both teropavimab and zinlirvimab for 23 viruses (31%), while 22 (29%) had a PPV between 62% and 75%, suggesting reduced susceptibility to both bNAbs as soon as primary infection. The surveillance of TDR evidenced at the time of PHI is important with regard to new strategies for HIV patients with virological failure and global implementation of PrEP using NRTI, INI such as recently approved injectable cabotegravir, and future long-acting drugs such as lenacapavir and bNAbs., (© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.) more...
- Published
- 2024
- Full Text
- View/download PDF